[Protracted rheumatologic manifestations in travelers].

Protracted rheumatological manifestations especially arthralgia and or polyarthritis may occur as a consequence of a wide range of pathogens including viral, bacterial and parasites. Few pathogenetic mechanisms leading to these clinical presentations have been suggested including a direct invasion of the synovial cells by the pathogens, immune complex formation, and others. The natural history of infectious arthritis/arthralgia is altogether benign, with full recovery and without sequelae, albeit sometimes very long. Diagnosis of infections-related arthralgia/arthritis is important since these diseases have a better prognosis, and can relieve anxiety among patients who are afraid of developing a chronic rheumatic disease. Since many patients will seek medical advice with these chronic complaints a long time after travel, physicians should be aware of the possible association between these complaints and remote travel. Thus, travel history should be mandatory, even in a rheumatologic setting.

Breast cancer in women suffering from serious mental illness.

BACKGROUND: Breast cancer is a major public health concern and the most common cause of cancer-related mortality among women. Compared with the general population, schizophrenia patients have been reported to have lower or similar rates of breast cancer despite several risk factors such as excess smoking, obesity and hyperprolactinemia. However, it has been argued that psychiatric morbidity itself may be the confounding factor that affects cancer incidence and not particularly schizophrenia. OBJECTIVE: To evaluate the frequency of breast cancer in a large cohort of female schizophrenia patients utilizing tertiary psychiatric care and to compare it with that of female inpatients with other serious mental illness (SMI). METHOD: Data were analyzed from a cohort of 2011 female schizophrenia patients and 6243 female SMI patients. All patient's records in the database were meshed with records of the Israeli National Cancer Registry to identify pathologically confirmed cancer co-morbidity. Cancer incidence rates among patients were compared with the expected incidence in age matched general population for the same time interval. RESULTS: Among 2011 female schizophrenia patients, 51 (2.5%) developed breast cancer vs. 83 (1.3%) breast cancer cases amongst SMI patients. The standardized incidence ratios (SIR) for breast cancer were low for both patient groups; 0.63 (95% CI, 0.47-0.83) and 0.54 (95% CI, 0.43-0.67) (schizophrenia and SMI respectively). CONCLUSIONS: The findings emphasize that reduced risk of breast cancer is found in a tertiary care cohort of female schizophrenia patients. Yet, breast and ovarian cancer screening for all women who are on long term drugs that induce weight gain or hyperprolactinemia should not be neglected. Our study emphasizes the probable contribution of environmental factors to the mechanisms responsible for this lower risk.

Does the use of folic acid increase the risk of twinning?

The increased rates of twinning and the increased consumption of folic acid are two parallel processes described in recent years. However, the possible association between an increased incidence of twin pregnancies and periconceptional folic acid supplementation remains controversial. Whereas the data indicating that when folic acid levels are increased to the range required for reducing the incidence of neural tube defects, the data pertaining to the increase in twinning rate are significantly incoherent and are flawed by serious confounders, such as fertility treatments and maternal age. The only plausible theory connecting methyltetrahydrofolate reductase mutation, folic acid, and twinning has not been confirmed. In addition, temporal and dose-effect relationships have not been established. Because of the lack of coherence, questionable plausibility, and no clear dose-effect and temporal relationships, a cause (folic acid supplementation) and effect (increased twinning rate) association cannot be, at present, accepted. Thus, the established policy of peri-conceptional folic acid supplementation to reduce the incidence of neural tube defects should be continued.

Timing of cord clamping revisited.

Although cord cutting has been performed since the beginning of mankind, the timing and advantages of early versus delayed cord clamping are still controversial. Early cord clamping (within the first 30 s after birth) is usually justified for potential prevention of postpartum hemorrhage and for immediate treatment of the newborn, but at the same time, may increase Rh-sensitization. Delayed cord clamping is performed after a period of 30 s during which 'placental transfusion' of approximately 80 mL of blood occurs. This amount seems to protect the baby from childhood anemia without increasing hypervolemia-related risks. In preterm infants, delayed clamping appears to reduce the risk of intraventricular hemorrhage and the need for neonatal transfusion. Obtaining cord blood for future autologous transplantation of stem cells needs early clamping and seems to conflict with the infant's best interest. Although a tailored approach is required in the case of cord clamping, the balance of available data suggests that delayed cord clamping should be the method of choice.

Mutational analysis of the hMSH6 gene in familial and early-onset colorectal and endometrial cancer in Israeli patients.

Familial colorectal cancer (CRC) is noted in about 15% of incident CRC cases, and at times is hallmarked by an age at diagnosis less than 50 years. Familial adenomatous polyposis (FAP) and hereditary non-polyposis colon cancer (HNPCC) account for about 40% of familial cases. Thus, the majority of familial and early-onset CRC remain genetically elusive. Similarly, the majority of familial and early onset endometrial cancer (EC), the most prevalent extracolonic tumor in HNPCC, are genetically undefined. An attractive candidate is the hMSH6 gene. Israeli patients with early onset (age under 50 years) (n = 44) and familial nonsyndromic (n = 23) CRC, and women with familial clustering of EC or CRC (n = 12), and those diagnosed with EC at, or under, the age of 50 years (n = 5) were genotyped for germ-line mutations within the hMSH6 gene. Exon-specific PCR was followed by denaturing gradient gel electrophoresis (DGGE) analysis, complemented by DNA sequencing of abnormally migrating fragments. No patients displayed a truncating mutation, and 1 CRC patient harbored a novel missense mutation (V878A). In addition, 6 previously described polymorphisms were detected. In conclusion, mutations in the hMSH6 gene occur uncommonly in Israeli patients with familial and early-onset CRC and EC.